{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:48:36Z","timestamp":1794862116602,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcitonin Gene-Related Peptide targeting monoclonal antibodies (CGRP mAbs) were introduced for migraine prophylaxis in Sweden through the National Joint Introduction process to ensure an equal, cost-effective, and appropriate national use. This study aimed to assess prescriber adherence to treatment guidelines and evaluate patient treatment persistence during the national introduction of CGRP mAbs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this register-based cohort study, we followed individuals with a migraine diagnosis or dispensation of migraine drugs within Stockholm County from July 2018 to June 2022. We evaluated the guidelines for CGRP mAb treatment (erenumab, fremanezumab, or galcanezumab) according to four categories: 1) patient eligibility, 2) prescriber qualifications, 3) treatment evaluation, and 4) monitoring\/reporting. We used a Sankey diagram to illustrate treatment switching and discontinuation patterns and employed boxplots along with Kaplan-Meier estimates to assess the persistence to CGRP mAbs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 93,263 eligible individuals, 2266 (2%) had at least one CGRP mAb dispensation. Most (90%) had a prior migraine diagnosis at the first CGRP mAb dispensation, and 66% had been dispensed at least two prior prophylactic drugs against migraine. In nearly all cases (97%), CGRP mAb prescriptions were issued by neurology or headache specialists. Switching between CGRP mAbs was common and treatment persistence declined across successive sequences. Overall median treatment duration was 5.8\u2009months (interquartile range: 2.8\u201311.9\u2009months) and was longer for erenumab than fremanezumab and galcanezumab in sequence 1, but not in sequence 2. Kaplan\u2013Meier analysis revealed a 12-month persistence of 58% in sequence 1, 53% in sequence 2, and 46% in sequence 3. A higher persistence was observed for fremanezumab and galcanezumab compared with erenumab in sequence 1, while estimates were similar in sequence 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prescribers within Stockholm County adhere well to CGRP mAb treatment guidelines, with dispensations largely supported by a sound medical rationale, indicating appropriate integration into clinical practice. Guidance on switching between CGRP mAbs is limited and our findings show frequent switching and reduced persistence across sequences. These insights can help clinicians avoid unnecessary switches and optimize migraine care and resource use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-026-02322-1","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:46:19Z","timestamp":1773125179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis \u2013 a register-based cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Sofia","family":"Nordenmalm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickard E.","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Freyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Ingela M","family":"Nilsson Remahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wirdefeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Ekheden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2322_CR1","doi-asserted-by":"crossref","unstructured":"Collaborators, GBDH (2025) Global, regional, and national burden of headache disorders, 1990-2023. A systematic analysis for the Global burden of disease study 2023. Lancet Neurol 24(12):1005\u20131015","DOI":"10.2139\/ssrn.5533924"},{"issue":"2","key":"2322_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ (2023) Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 19(2):109\u2013117","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"2322_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1046\/j.1468-2982.2001.00218.x","volume":"21","author":"C Dahlof","year":"2001","unstructured":"Dahlof C, Linde M (2001) One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia 21(6):664\u2013671","journal-title":"Cephalalgia"},{"key":"2322_CR4","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","DOI":"10.1177\/0333102417738202"},{"issue":"4","key":"2322_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37(4):631\u2013649","journal-title":"Neurol Clin"},{"issue":"1","key":"2322_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12883-024-03600-8","volume":"24","author":"P Pozo-Rosich","year":"2024","unstructured":"Pozo-Rosich P, Carmo M, Muniz A, Armada B, Moya-Alarcon C, Pascual J (2024) Migraine treatment: quo vadis? real-world data study (2015-2022) in Spain. BMC Neurol 24(1):107","journal-title":"BMC Neurol"},{"issue":"1","key":"2322_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s10194-024-01918-9","volume":"25","author":"AC Rubio","year":"2024","unstructured":"Rubio AC, Arciniegas JA, Bolanos-Lopez JE, Gonzalez FJ, Gomez D, Mesa A et al (2024) Epidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022. J Headache Pain 25(1):226","journal-title":"J Headache Pain"},{"key":"2322_CR8","unstructured":"The National Board of Health and Welfare Statistical database on medicines. Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/statistik\/alla-statistikamnen\/lakemedel\/"},{"key":"2322_CR9","unstructured":"Eriksson I (2019). Introduction of New Medicines in Sweden (Thesis for Doctoral Degree). Karolinska Institutet. Available from: https:\/\/openarchive.ki.se\/articles\/thesis\/Introduction_of_new_medicines_in_Sweden\/26908534"},{"key":"2322_CR10","unstructured":"The New Therapies Council in Sweden National joint introduction. Available from: https:\/\/samverkanlakemedel.se\/process---ordnat-inforande\/national-joint-introduction"},{"key":"2322_CR11","unstructured":"Swedish Neuro Registries. Severe Neurovascular Headache. Available from: https:\/\/www.neuroreg.se\/en\/svar-neurovaskular-huvudvark\/"},{"issue":"1","key":"2322_CR12","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1038\/s41598-022-12545-2","volume":"12","author":"A Olesen","year":"2022","unstructured":"Olesen A, Schytz HW, Ostrowski SR, Topholm M, Nielsen K, Erikstrup C et al (2022) Low adherence to the guideline for the acute treatment of migraine. Sci Rep 12(1):8487","journal-title":"Sci Rep"},{"issue":"1","key":"2322_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-019-0971-6","volume":"20","author":"D Garcia-Azorin","year":"2019","unstructured":"Garcia-Azorin D, Santos-Lasaosa S, Gago-Veiga AB, Viguera Romero J, Guerrero-Peral AL (2019) Real world preventative drug management of migraine among Spanish neurologists. J Headache Pain 20(1):19","journal-title":"J Headache Pain"},{"issue":"1","key":"2322_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0333102416631959","volume":"37","author":"HH Altalib","year":"2017","unstructured":"Altalib HH, Fenton BT, Sico J, Goulet JL, Bathulapalli H, Mohammad A et al (2017) Increase in migraine diagnoses and guideline-concordant treatment in veterans, 2004-2012. Cephalalgia 37(1):3\u201310","journal-title":"Cephalalgia"},{"issue":"3","key":"2322_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00228-015-1983-z","volume":"72","author":"T Forslund","year":"2016","unstructured":"Forslund T, Wettermark B, Hjemdahl P (2016) Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin. Pharmacol 72(3):329\u2013338","journal-title":"Eur. J. Clin. Pharmacol"},{"issue":"9","key":"2322_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/eurjhf\/hft064","volume":"15","author":"R Zarrinkoub","year":"2013","unstructured":"Zarrinkoub R, Wettermark B, Wandell P, Mejhert M, Szulkin R, Ljunggren G et al (2013) The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 15(9):995\u20131002","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"2322_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/pds.5490","volume":"31","author":"L Rasmussen","year":"2022","unstructured":"Rasmussen L, Wettermark B, Steinke D, Pottegard A (2022) Core concepts in pharmacoepidemiology: measures of drug utilization based on individual-level drug dispensing data. Pharmacoepidemiol Drug Saf 31(10):1015\u20131026","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2322_CR18","unstructured":"The Dental and Pharmaceutical Benefits Agency. Pharmaceutical Benefits Board (2023) Documentation for reimbursement decision - Re-evaluation of CGRP inhibitors. Case No. 1615\/2022. [Swedish]. Available from: https:\/\/www.tlv.se\/lakemedelsforetag\/omprovning-av-lakemedel\/arkiv-avslutade-omprovningar-lakemedel\/2023-06-19-cgrp-hammarna-kvarstar-i-hogkostnadsskyddet-till-sankt-pris-med-oforandrad-subventionsbegransning.html"},{"key":"2322_CR19","unstructured":"Posit team. RStudio: Integrated Development Environment for R. (2023. Available from: Posit Software, PBC. http:\/\/www.posit.co\/ Boston, MA"},{"key":"2322_CR20","doi-asserted-by":"crossref","unstructured":"Zebenholzer K, Gleiss A, Reichardt B, Gall W, Wober C (2025) Prescription of monoclonal antibodies against calcitonin gene-related peptide for the prophylaxis of migraine in Austria: a retrospective, longitudinal analysis of nationwide insurance data. Eur J Neurol 32(12):e70440","DOI":"10.1111\/ene.70440"},{"key":"2322_CR21","unstructured":"Government Offices of Sweden (2025) Assignment to the national Board of Health and Welfare to develop national guidelines for migraine care [Swedish], editor.) Ref. No. S2025\/01276. in: ministry of health and social affairs"},{"issue":"5","key":"2322_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10654-025-01226-9","volume":"40","author":"JF Ludvigsson","year":"2025","unstructured":"Ludvigsson JF, Bergman D, Lundgren CI, Sundquist K, Geijerstam JA, Glenngard AH et al (2025) The healthcare system in Sweden. Eur J Epidemiol 40(5):563\u2013579","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"2322_CR23","doi-asserted-by":"publisher","first-page":"333102425134864","DOI":"10.1177\/03331024251348648","volume":"45","author":"T Wennersten","year":"2025","unstructured":"Wennersten T, Lindh JD, Nilsson Remahl AIM, Andersson ML, von Euler M, Wirdefeldt K et al (2025) Higher socioeconomic status is associated with dispensation of monoclonal antibodies against calcitonin gene-related peptide in migraine: a nested case-control study. Cephalalgia 45(6):3331024251348648","journal-title":"Cephalalgia"},{"key":"2322_CR24","doi-asserted-by":"crossref","unstructured":"Ray R, Virk GS, Regmi N, Shafiq MM, Siddique R, Elfatih Elamin A et al (2025) Patient adherence and long-term tolerability of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in migraine prevention: a systematic Review. Cureus 17(8):e91347","DOI":"10.7759\/cureus.91347"},{"issue":"1","key":"2322_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/head.14827","volume":"65","author":"A de Dios","year":"2025","unstructured":"de Dios A, Pages-Puigdemont N, Ojeda S, Riera P, Pelegrin R, Morollon N et al (2025) Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine. Headache 65(1):24\u201334","journal-title":"Headache"},{"issue":"8","key":"2322_CR26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jval.2024.04.002","volume":"27","author":"A Smith","year":"2024","unstructured":"Smith A, Finnigan K, Clarke S, Barry M, Utilization GC (2024) Expenditure, and treatment patterns associated with calcitonin gene-related peptide monoclonal antibodies reimbursed subject to a Managed access protocol in Ireland. Value Health 27(8):1039\u20131045","journal-title":"Value Health"},{"key":"2322_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R (2022) Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adherence 16:821\u2013839","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2322_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K et al (2023) The sense of stopping migraine prophylaxis. J Headache Pain 24(1):9","journal-title":"J Headache Pain"},{"issue":"11","key":"2322_CR29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/17512433.2024.2417655","volume":"17","author":"M Waliszewska-Prosol","year":"2024","unstructured":"Waliszewska-Prosol M, Raffaelli B, Straburzynski M, Martelletti P (2024) Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists. Expert Rev Clin Pharmacol 17(11):1039\u20131051","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2322_CR30","doi-asserted-by":"crossref","unstructured":"van Veelen N, van der Arend BWH, Hiele E, van Zwet EW, Terwindt GM (2025) Switching from ligand to receptor anti-calcitonin gene-related peptide (CGRP) antibodies or vice versa in non-responders: a controlled cohort study. Eur J Neurol 32(1):e16542","DOI":"10.1111\/ene.16542"},{"issue":"4","key":"2322_CR31","doi-asserted-by":"publisher","first-page":"333102423116051","DOI":"10.1177\/03331024231160519","volume":"43","author":"LF Iannone","year":"2023","unstructured":"Iannone LF, Burgalassi A, Vigani G, Tabasso G, De Cesaris F, Chiarugi A et al (2023) Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia 43(4):3331024231160519","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"2322_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42(4\u20135):291\u2013301","journal-title":"Cephalalgia"},{"issue":"4","key":"2322_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/head.14865","volume":"65","author":"A Jaimes","year":"2025","unstructured":"Jaimes A, Gomez A, Pajares O, Rodriguez-Vico J (2025) Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: a retrospective cohort study. Headache 65(4):619\u2013630","journal-title":"Headache"},{"issue":"1","key":"2322_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-025-02087-z","volume":"26","author":"FM Amin","year":"2025","unstructured":"Amin FM, Linnet T, Cullum CK, Do TP, Younis S (2025) Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study. J Headache Pain 26(1):152","journal-title":"J Headache Pain"},{"key":"2322_CR35","unstructured":"Region Stockholm\u2019s Drug and Therapeutics Committee, The Expert Group of Neurological Disorders. CGRP Inhibitor Treatment for Chronic Migraine [Swedish: CGRP-h\u00e4mmarbehandling - vid kronisk migr\u00e4n] Janusinfo 2024 . Available from: https:\/\/janusinfo.se\/behandling\/expertgruppsutlatanden\/nervsystemetssjukdomar\/nervsystemetssjukdomar\/cgrphammarbehandlingvidkroniskmigran.5.49ad13d018a82e14be630b5a.html"},{"issue":"4","key":"2322_CR36","doi-asserted-by":"publisher","first-page":"333102424130538","DOI":"10.1177\/03331024241305381","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, Al-Khazali HM, Ambrosini A, Ashina S et al (2025) Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia 45(4):3331024241305381","journal-title":"Cephalalgia"},{"key":"2322_CR37","unstructured":"The National Board of Health and Welfare. National Patient Register. Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-patient-register\/"},{"issue":"6","key":"2322_CR38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1468-2982.2004.00703.x","volume":"24","author":"M Linde","year":"2004","unstructured":"Linde M, Dahlof C (2004) Attitudes and burden of disease among self-considered migraineurs-a nation-wide population-based survey in Sweden. Cephalalgia 24(6):455\u2013465","journal-title":"Cephalalgia"},{"key":"2322_CR39","doi-asserted-by":"crossref","unstructured":"Musial L, Kheloussi S (2023) Prior authorization requirements for calcitonin gene-related peptide antagonists. Am J Manag Care 29(4):e117\u2013e23","DOI":"10.37765\/ajmc.2023.89352"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02322-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02322-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02322-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:43:47Z","timestamp":1781639027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02322-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2322"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02322-1","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Swedish Ethical Review Authority (initial approval: case number 2021\u201305078, 2021\u201310-25; amendments: case number 2022\u201300372-02, 2022\u201303-20; 2023\u201303380-02, 2023\u201306-08; and 2023\u201307478-02, 2024\u201301-05).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Patient consent was waived by the Swedish Ethical Review Authority after a benefit-risk assessment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"An earlier version of this study was presented at the European Drug Utilization (EuroDURG) Conference, Uppsala, July 2025 (Abstract number 107, Abstract book page 193, URL:\n                      \n                      ), and at the 19th European Headache Congress (EHC), Lisbon, December 2025 (Abstract number P399, Abstract book page 245, URL: https:\/\/headache-congress.org\/programme-abstracts\/abstract-booklet-2025\/\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conference presentations"}},{"value":"The authors Rickard Malmstr\u00f6m, A. Ingela M Nilsson Remahl, Karin Wirdefeldt, and Isabella Ekheden are members of Region Stockholm\u2019s Drug and Therapeutics Committee. The remaining authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}